Ladenburg Thalmann Initiates Coverage On Coeptis Therapeutics with Buy Rating, Announces Price Target of $3
Portfolio Pulse from Benzinga Newsdesk
Ladenburg Thalmann analyst Aydin Huseynov has initiated coverage on Coeptis Therapeutics (NASDAQ:COEP) with a Buy rating and a price target of $3.
September 22, 2023 | 11:49 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Coeptis Therapeutics has been initiated with a Buy rating by Ladenburg Thalmann, with a price target of $3.
The initiation of coverage by Ladenburg Thalmann with a Buy rating indicates a positive outlook for Coeptis Therapeutics. The price target of $3 suggests potential upside, which could positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100